Get the Stockscreener App
27.85
1.31%
-0.37
After Hours:
27.85
Cg Oncology Inc stock is traded at $27.85, with a volume of 356.58K.
It is down -1.31% in the last 24 hours and down -7.17% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$28.22
Open:
$28.53
24h Volume:
356.58K
Relative Volume:
0.54
Market Cap:
$2.12B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-21.93
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
-2.35%
1M Performance:
-7.17%
6M Performance:
-23.82%
1Y Performance:
-38.49%
1-Day Range:
$27.84
$29.07
1-Week Range:
$27.10
$29.42
52-Week Range:
$25.77
$48.05
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
27.85 | 2.12B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
UroGen Plots Expansion, Brings In A New Asset - News & Insights
Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Buy” by Analysts - Defense World
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Mirae Asset Global Investments Co. Ltd. Buys Shares of 2,254 CG Oncology, Inc. (NASDAQ:CGON) - Defense World
China Universal Asset Management Co. Ltd. Acquires New Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Market Watch Highlights: Cg Oncology Inc (CGON) Ends on an Upturn Note at 30.32 - The Dwinnex
CGON Stock Sees Surge of Approximately 0.10% in Last Five Days - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62% - Yahoo Finance
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
CG Oncology, Inc. (NASDAQ:CGON) Stock Holdings Boosted by JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Analysts Offer Predictions for CG Oncology FY2025 Earnings - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cantor Fitzgerald Comments on CG Oncology FY2025 Earnings - MarketBeat
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
This CG Oncology Insider Reduced Their Stake By 16% - Simply Wall St
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? - MSN
Cg Oncology Inc (CGON) Volatility Hits 4.53%: What Good Investors Need To Be Aware Of - Stocks Register
Cg oncology director Leonard Post sells shares worth $29,660 By Investing.com - Investing.com Australia
Cg oncology director Leonard Post sells shares worth $29,660 - Investing.com India
CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares - MarketBeat
CG Oncology (NASDAQ:CGON) Earns “Buy” Rating from HC Wainwright - Defense World
CG Oncology amends executive compensation agreements By Investing.com - Investing.com Canada
CG Oncology amends executive compensation agreements - Investing.com India
A First Take On CG Oncology (NASDAQ:CGON) - Seeking Alpha
CG Oncology's (CGON) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Pfizer study impact on CG Oncology to be minimal, says H.C. Wainwright - TipRanks
CG Oncology (NASDAQ:CGON) Research Coverage Started at TD Cowen - Defense World
TD Cowen Initiates Coverage of CG Oncology (CGON) with Buy Recommendation - MSN
CG Oncology (NASDAQ:CGON) Stock Price Up 7.5%Time to Buy? - MarketBeat
TD Cowen initiates CG Oncology stock with Buy rating By Investing.com - Investing.com Canada
CG Oncology (NASDAQ:CGON) Now Covered by TD Cowen - MarketBeat
TD Cowen initiates CG Oncology stock with Buy rating - Investing.com
CG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 5.3% in December - MarketBeat
CG Oncology (NASDAQ:CGON) Stock Price Down 6.9%Time to Sell? - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Buy” by Brokerages - Defense World
Head-To-Head Analysis: Atyr PHARMA (NASDAQ:ATYR) versus CG Oncology (NASDAQ:CGON) - Defense World
CG Oncology : Reports Third Quarter 2024 Financial Results and Provides Business Updates Form 8 K - Marketscreener.com
CG Oncology (NASDAQ:CGON) Shares Up 2.5%Still a Buy? - MarketBeat
Comparing Tarsus Pharmaceuticals (NASDAQ:TARS) and CG Oncology (NASDAQ:CGON) - Defense World
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):